DK0640619T4 - Erythropoietinanloger med yderligere glycosyleringssteder - Google Patents

Erythropoietinanloger med yderligere glycosyleringssteder

Info

Publication number
DK0640619T4
DK0640619T4 DK94112732T DK94112732T DK0640619T4 DK 0640619 T4 DK0640619 T4 DK 0640619T4 DK 94112732 T DK94112732 T DK 94112732T DK 94112732 T DK94112732 T DK 94112732T DK 0640619 T4 DK0640619 T4 DK 0640619T4
Authority
DK
Denmark
Prior art keywords
glycosylation sites
additional glycosylation
erythropoietin analogs
hepo
analogue
Prior art date
Application number
DK94112732T
Other languages
Danish (da)
English (en)
Other versions
DK0640619T3 (da
Inventor
Steven G Elliot
Thomas E Byrne
Original Assignee
Kirin Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22319789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0640619(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kirin Amgen Inc filed Critical Kirin Amgen Inc
Application granted granted Critical
Publication of DK0640619T3 publication Critical patent/DK0640619T3/da
Publication of DK0640619T4 publication Critical patent/DK0640619T4/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/505Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Fruits And Vegetables (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
DK94112732T 1993-08-17 1994-08-16 Erythropoietinanloger med yderligere glycosyleringssteder DK0640619T4 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10801693A 1993-08-17 1993-08-17

Publications (2)

Publication Number Publication Date
DK0640619T3 DK0640619T3 (da) 1998-02-02
DK0640619T4 true DK0640619T4 (da) 2005-04-18

Family

ID=22319789

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94112732T DK0640619T4 (da) 1993-08-17 1994-08-16 Erythropoietinanloger med yderligere glycosyleringssteder

Country Status (27)

Country Link
EP (1) EP0640619B2 (ja)
JP (3) JP2938572B2 (ja)
KR (2) KR100328769B1 (ja)
CN (1) CN1057534C (ja)
AT (1) ATE155796T1 (ja)
AU (1) AU677097B2 (ja)
CA (1) CA2147124C (ja)
CZ (3) CZ291229B6 (ja)
DE (2) DE69404401T3 (ja)
DK (1) DK0640619T4 (ja)
ES (1) ES2105442T5 (ja)
FI (1) FI117136B (ja)
GR (1) GR3024815T3 (ja)
HK (1) HK1001589A1 (ja)
HU (1) HU220334B (ja)
IL (4) IL192290A0 (ja)
LU (1) LU90850I2 (ja)
LV (1) LV10972B (ja)
NL (1) NL300075I2 (ja)
NO (2) NO323104B1 (ja)
NZ (1) NZ273134A (ja)
RU (1) RU2159814C2 (ja)
SI (1) SI0640619T2 (ja)
SK (1) SK282003B6 (ja)
UA (1) UA49793C2 (ja)
WO (1) WO1995005465A1 (ja)
ZA (1) ZA946122B (ja)

Families Citing this family (234)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5696250A (en) * 1995-02-15 1997-12-09 Amgen Inc. DNA encoding megakaryocyte growth and development factor analogs
US5989538A (en) * 1995-02-15 1999-11-23 Amgen Inc. Mpl ligand analogs
AU6964196A (en) * 1995-10-09 1997-04-30 Pharmacia & Upjohn Company An acceptor polypeptide for an n-acetylgalactosaminyltransferase
KR100400637B1 (ko) * 1996-02-06 2004-03-10 씨제이 주식회사 생물학적으로유용한펩타이드
ATE247667T1 (de) 1996-03-14 2003-09-15 Genentech Inc Gdnf-rezeptor und dessen verwendung
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
DK0902085T3 (da) * 1997-09-01 2004-04-05 Aventis Pharma Gmbh Rekombinant human erythropoietin med fordelagtig glycosyleringsprofil
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
EP1088084B1 (en) 1998-06-15 2006-09-13 GTC Biotherapeutics, Inc. Erythropoietin analog-human serum albumin fusion protein
ATE355303T1 (de) * 1998-10-23 2006-03-15 Amgen Inc Methoden und zusammensetzungen zur prävention und behandlung der anämie
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
WO2000047741A1 (en) * 1999-02-12 2000-08-17 Amgen Inc. Glycosylated leptin compositions and related methods
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7410941B1 (en) 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
IL145785A0 (en) * 1999-05-07 2002-07-25 Genentech Inc Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same
US6555343B1 (en) 1999-05-07 2003-04-29 Genentech Inc. Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
US6831060B2 (en) 1999-05-07 2004-12-14 Genentech, Inc. Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP2003514552A (ja) * 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
DK1274728T3 (da) * 2000-04-21 2008-09-01 Amgen Inc Fremgangsmåder og sammensætninger til forebyggelse og behandling af anæmi
ATE291436T2 (de) * 2000-05-15 2005-04-15 Hoffmann La Roche Flüssige arzneizubereitung enthaltend ein erythropoietin derivat
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
JP5490972B2 (ja) 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
WO2002013860A1 (fr) 2000-08-11 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Preparations stabilisees contenant un anticorps
KR101229995B1 (ko) * 2000-12-11 2013-02-06 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
AU2002222740A1 (en) * 2000-12-11 2002-06-24 Cheil Jedang Corporation Fusion protein having the enhanced in vivo activity of erythropoietin
KR100645843B1 (ko) 2000-12-20 2006-11-14 에프. 호프만-라 로슈 아게 에리트로포이에틴 접합체
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
ATE361089T1 (de) 2001-02-02 2007-05-15 Ortho Mcneil Pharm Inc Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin
ES2393733T3 (es) 2001-03-07 2012-12-27 Merck Patent Gmbh Tecnología de expresión para proteínas que contienen una fracción de anticuerpo de isotipo híbrido
WO2002072615A1 (fr) 2001-03-09 2002-09-19 Chugai Seiyaku Kabushiki Kaisha Methode de purification de proteines
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
JP4236934B2 (ja) 2001-04-17 2009-03-11 中外製薬株式会社 界面活性剤の定量方法
RU2306320C9 (ru) 2001-05-03 2008-01-27 Мерк Патент Гмбх Рекомбинантное опухолеспецифичное антитело (варианты) и его применение
US6930086B2 (en) 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
AU2002357019A1 (en) 2001-11-28 2003-06-10 Ortho-Mcneil Pharmaceutical, Inc. Erythropoietin dosing regimen for treating anemia
KR100467750B1 (ko) * 2001-11-29 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
KR100467751B1 (ko) * 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
CN100390282C (zh) 2001-12-04 2008-05-28 默克专利有限公司 具有调节的选择性的il-2融合蛋白
NZ533124A (en) 2001-12-07 2005-11-25 Crucell Holland B Production of viruses, viral isolates and vaccines
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
AU2003218045A1 (en) 2002-03-11 2003-09-29 Ortho Mcneil Pharmaceutical, Inc Methods for shp1 mediated neuroprotection
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
KR20060019501A (ko) * 2002-07-01 2006-03-03 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 응답 세포, 조직 및 기관을 보호, 회복 및 향상시키기위한 재조합 조직 보호 사이토카인 및 이를 코딩하는 핵산
WO2004009627A1 (en) * 2002-07-19 2004-01-29 Cangene Corporation Pegylated erythropoietic compounds
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20060058511A1 (en) 2002-08-27 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing protein solution preparation
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
EP1539960B1 (en) * 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistant modified interferon alpha polypeptides
DE20321793U1 (de) 2002-09-11 2010-06-02 Fresenius Kabi Deutschland Gmbh Hydroxyalkylstärke-Derivate
SI1561756T1 (sl) 2002-09-11 2016-02-29 Chugai Seiyaku Kabushiki Kaisha Postopek čiščenja proteinov
CA2495242A1 (en) 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh Hasylated polypeptides, especially hasylated erythropoietin
EP1681303B1 (en) 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
AU2003273413A1 (en) 2002-10-08 2004-05-04 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
AU2003301332B2 (en) * 2002-10-17 2008-06-12 Pharming Intellectual Property B.V. Protein modification
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7169904B2 (en) 2002-12-17 2007-01-30 Emd Lexigen Research Center Corp. Immunocytokine sequences and uses thereof
CN100383238C (zh) 2003-05-09 2008-04-23 克鲁塞尔荷兰公司 E1-永生化的细胞培养物及培养所述细胞以提高从中获取的产物产量的方法
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
KR20070008519A (ko) 2003-09-29 2007-01-17 워렌 파마슈티칼즈 인코포레이티드 패혈증 및 유착 형성의 치료 및 예방용 조직 보호성사이토카인
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
DE502004011252D1 (de) 2003-12-30 2010-07-15 Augustinus Bader Verwendung des erythropoietins zur regeneration von lebergewebe
DE102004063927A1 (de) 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
WO2005092928A1 (en) 2004-03-11 2005-10-06 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
WO2009100255A2 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US9988427B2 (en) 2005-05-13 2018-06-05 Charite Universitaetsmedizen-Berlin Erythropoietin variants
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
CN100432107C (zh) * 2005-10-25 2008-11-12 北京大学 具有促红细胞生长因子活性的蛋白质及其用途
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
US7972810B2 (en) 2005-12-08 2011-07-05 Amgen Inc. Production of glycoproteins using manganese
WO2007067564A2 (en) 2005-12-08 2007-06-14 Amgen Inc. Improved host cells and culture methods
DE102006004008A1 (de) 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
EP1997505A4 (en) 2006-03-22 2013-02-13 Chugai Pharmaceutical Co Ltd PREPARATION OF ERYTHROPOIETIN SOLUTION
CN101062407A (zh) 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 促红细胞生成素在预防或治疗视网膜损伤中的用途
WO2007136752A2 (en) 2006-05-19 2007-11-29 Glycofi, Inc. Erythropoietin compositions
JP2009544327A (ja) 2006-07-21 2009-12-17 ノヴォ ノルディスク アー/エス O−結合型グリコシル化配列によるペプチドのグリコシル化
CA2657307A1 (en) 2006-07-21 2008-01-24 Amgen Inc. Method of detecting and/or measuring hepcidin in a sample
JPWO2008023725A1 (ja) 2006-08-22 2010-01-14 中外製薬株式会社 末梢神経障害の予防および/または治療剤
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
CN101337988B (zh) * 2006-10-31 2013-01-09 沈阳三生制药有限责任公司 一种新的促红细胞生成素类似物
WO2008058942A2 (en) 2006-11-13 2008-05-22 Charite - Universitätsmedezin Berlin Method of cell culture and method of treatment comprising a vepo protein variant
WO2008065372A2 (en) 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment
AR065613A1 (es) 2007-03-09 2009-06-17 Chugai Pharmaceutical Co Ltd Agentes de proteccion para organos transplantados
KR20150064246A (ko) 2007-04-03 2015-06-10 바이오제너릭스 게엠베하 글리코페길화 g―csf를 이용하는 치료 방법
ES2551123T3 (es) 2007-06-12 2015-11-16 Ratiopharm Gmbh Proceso mejorado para la producción de azúcares de nucleótido
WO2008151841A2 (en) * 2007-06-15 2008-12-18 University Of Zurich Treatment for alzheimer' s disease
CN103113464B (zh) * 2007-07-02 2014-08-20 沈阳三生制药有限责任公司 天然人促红细胞生成素类似物
CN103073631A (zh) * 2007-07-02 2013-05-01 沈阳三生制药有限责任公司 一种促红细胞生成素类似物
WO2009010107A1 (en) 2007-07-19 2009-01-22 Hannelore Ehrenreich Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
ES2750254T3 (es) 2007-09-27 2020-03-25 Amgen Inc Formulaciones farmacéuticas
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
US9175078B2 (en) 2008-01-25 2015-11-03 Amgen Inc. Ferroportin antibodies and methods of use
EP2095829A1 (en) 2008-02-27 2009-09-02 LEK Pharmaceuticals D.D. Selenium containing modifying agents and conjugates
CN101965200B (zh) 2008-02-27 2013-06-19 诺沃-诺迪斯克有限公司 缀合的因子ⅷ分子
US20110137011A1 (en) 2008-04-21 2011-06-09 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
MX2010011717A (es) 2008-05-01 2010-11-30 Amgen Inc Anticuerpos anti-hepcidina y metodos de uso.
US20120172299A1 (en) 2008-09-23 2012-07-05 F. Hoffmann-La Roche Ag Purification of erythropoietin
CN107022020A (zh) 2008-09-26 2017-08-08 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
AU2009313902B9 (en) 2008-11-13 2014-03-27 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation of BMP-6
KR101666144B1 (ko) * 2009-02-19 2016-10-13 셀리아 파마슈티칼즈 에이피에스 리포펩티드를 정제하는 방법
US20100272816A1 (en) 2009-04-27 2010-10-28 Wolfgang Rudinger Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
EP3009447B1 (en) 2009-07-24 2018-06-06 Dr. Reddy's Laboratories, Ltd. Production of erythropoiesis stimulating protein using metal ions
WO2011024025A1 (en) * 2009-08-28 2011-03-03 Avesthagen Limited An erythropoietin analogue and a method thereof
MX344382B (es) 2009-10-23 2016-12-14 Amgen Inc * Adaptador de vial y sistema.
ES2545411T5 (es) 2010-06-07 2024-04-05 Amgen Inc Dispositivo de administración de fármaco
US20120115637A1 (en) 2010-06-30 2012-05-10 Nike, Inc. Golf Balls Including A Crosslinked Thermoplastic Polyurethane Cover Layer Having Improved Scuff Resistance
US8193296B2 (en) 2010-06-30 2012-06-05 Nike, Inc. Golf balls including crosslinked thermoplastic polyurethane
RU2451071C1 (ru) * 2010-12-10 2012-05-20 Российская Федерация, от имени которой выступает Министерство образования и науки Российской Федерации (Минобрнауки России) Штамм гибридных культивируемых клеток животных mus musculus - продуцент моноклональных антител к рекомбинантному эритропоэтину человека (варианты)
US9480624B2 (en) 2011-03-31 2016-11-01 Amgen Inc. Vial adapter and system
LT2699293T (lt) 2011-04-20 2019-04-25 Amgen Inc. Automatinio purškimo prietaisas
US8979676B2 (en) 2011-08-23 2015-03-17 Nike, Inc. Multi-core golf ball having increased initial velocity at high swing speeds relative to low swing speeds
US9089739B2 (en) 2011-08-23 2015-07-28 Nike, Inc. Multi-core golf ball having increased initial velocity
KR102084171B1 (ko) 2011-10-14 2020-04-14 암젠 인크 주사기 및 어셈블리 방법
KR101443257B1 (ko) * 2011-10-18 2014-09-19 주식회사 종근당 낮은 등전점을 갖는 에리스로포이에틴 유사체의 정제방법
CN102788720B (zh) * 2012-06-05 2016-01-06 西北大学 一种滤膜辅助分离生物样本中糖蛋白全n-连接糖链及其鉴别方法
SI3081249T1 (sl) 2012-11-21 2021-03-31 Amgen Inc. Naprava za dajanje zdravila
CN103864913A (zh) 2012-12-18 2014-06-18 联亚生技开发股份有限公司 重组蛋白
TWI639449B (zh) 2013-03-15 2018-11-01 美商安美基公司 用於注射器之匣盒
CA2904725C (en) 2013-03-15 2022-04-12 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
CN110041427B (zh) 2013-03-15 2023-05-23 本质生命科学有限公司 抗铁调素抗体及其用途
WO2014149357A1 (en) 2013-03-22 2014-09-25 Amgen Inc. Injector and method of assembly
US11097055B2 (en) 2013-10-24 2021-08-24 Amgen Inc. Injector and method of assembly
AU2014340174B2 (en) 2013-10-24 2019-09-12 Amgen Inc. Drug delivery system with temperature-sensitive control
KR101414897B1 (ko) 2013-11-29 2014-07-04 씨제이헬스케어 주식회사 다베포에틴 알파의 정제 방법
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
CN106413779B (zh) 2014-05-07 2020-06-05 安姆根有限公司 具有减震元件的自助注射器
JP6822843B2 (ja) 2014-06-03 2021-01-27 アムジエン・インコーポレーテツド 薬物送達装置によって収集されたデータを遠隔で処理するためのシステム及び方法
EP3194429A4 (en) 2014-09-18 2018-06-13 Askgene Pharma, Inc. Novel feline erythropoietin receptor agonists
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
EP3943135A3 (en) 2014-10-14 2022-06-29 Amgen Inc. Drug injection device with visual and audible indicators
ES2785311T3 (es) 2014-12-19 2020-10-06 Amgen Inc Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
US10799630B2 (en) 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
EP3258988B1 (en) 2015-02-17 2019-08-28 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
US11806509B2 (en) 2015-02-27 2023-11-07 Amgen Inc. Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
EP3386573B1 (en) 2015-12-09 2019-10-02 Amgen Inc. Auto-injector with signaling cap
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
JP6906497B2 (ja) * 2016-03-09 2021-07-21 Jcrファーマ株式会社 変異型ヒトエリスロポエチンの製造方法
EP4035711A1 (en) 2016-03-15 2022-08-03 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
US10988284B2 (en) 2016-05-13 2021-04-27 Amgen Inc. Vial sleeve assembly
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
GB2550418A (en) 2016-05-20 2017-11-22 Laing Peter An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
EP3532127A1 (en) 2016-10-25 2019-09-04 Amgen Inc. On-body injector
EP3570917A1 (en) 2017-01-17 2019-11-27 Amgen Inc. Injection devices and related methods of use and assembly
WO2018152073A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Insertion mechanism for drug delivery device
CA3048520A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
JP6258536B1 (ja) * 2017-03-03 2018-01-10 協和発酵キリン株式会社 ダルベポエチン組成物の製造方法およびダルべポエチン産生細胞の培養方法
CA3050927A1 (en) 2017-03-06 2018-09-13 Brian Stonecipher Drug delivery device with activation prevention feature
KR102627069B1 (ko) 2017-03-07 2024-01-18 암겐 인코포레이티드 과압에 의한 바늘 삽입
IL268386B2 (en) 2017-03-09 2023-11-01 Amgen Inc Insertion mechanism for a drug delivery device
EP3570871B1 (en) 2017-03-20 2020-11-18 H. Hoffnabb-La Roche Ag Method for in vitro glycoengineering of an erythropoiesis stimulating protein
EP4241807A3 (en) 2017-03-28 2023-10-11 Amgen Inc. Plunger rod and syringe assembly system and method
JP2020522263A (ja) 2017-06-06 2020-07-30 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のためのエリスロポエチンおよびアナログ
JP7200134B2 (ja) 2017-06-08 2023-01-06 アムジエン・インコーポレーテツド トルク駆動式薬物送達デバイス
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
MX2019015472A (es) 2017-06-22 2020-02-19 Amgen Inc Reduccion del impacto/choque de la activacion del mecanismo.
AU2018290302B2 (en) 2017-06-23 2024-02-29 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
WO2019014014A1 (en) 2017-07-14 2019-01-17 Amgen Inc. NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM
WO2019018169A1 (en) 2017-07-21 2019-01-24 Amgen Inc. PERMEABLE GAS SEALING ELEMENT FOR MEDICINE CONTAINER AND METHODS OF ASSEMBLY
US11484648B2 (en) 2017-07-25 2022-11-01 Amgen Inc. Drug delivery device with container access system and related method of assembly
EP4085942A1 (en) 2017-07-25 2022-11-09 Amgen Inc. Drug delivery device with gear module and related method of assembly
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
EP3668567A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
EP3691717B1 (en) 2017-10-04 2023-02-08 Amgen Inc. Flow adapter for drug delivery device
EP4257164A3 (en) 2017-10-06 2024-01-17 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
IL273323B1 (en) 2017-10-09 2024-06-01 Amgen Inc Drug delivery device with drive assembly and related assembly method
EP3703778A1 (en) 2017-11-03 2020-09-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
EP3707075A1 (en) 2017-11-06 2020-09-16 Amgen Inc. Fill-finish assemblies and related methods
EP3706830A1 (en) 2017-11-06 2020-09-16 Amgen Inc. Drug delivery device with placement and flow sensing
CN111225696B (zh) 2017-11-10 2023-07-18 安进公司 用于药物递送装置的柱塞
AU2018368338A1 (en) 2017-11-16 2020-04-09 Amgen Inc. Autoinjector with stall and end point detection
AU2018368340B2 (en) 2017-11-16 2024-03-07 Amgen Inc. Door latch mechanism for drug delivery device
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
US20210128844A1 (en) 2018-07-24 2021-05-06 Amgen Inc. Delivery devices for administering drugs
EP3826701A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Delivery devices for administering drugs
MA53320A (fr) 2018-07-31 2021-11-03 Amgen Inc Ensemble de trajet de fluide pour dispositif d'administration de médicament
WO2020068623A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
AR113091A1 (es) 2018-09-27 2020-01-22 Univ Nacional Del Litoral Eritropoyetina humana modificada
EP3856283A1 (en) 2018-09-28 2021-08-04 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
AU2019352616A1 (en) 2018-10-02 2021-03-18 Amgen Inc. Injection systems for drug delivery with internal force transmission
TW202408605A (zh) 2018-10-05 2024-03-01 美商安進公司 具有劑量指示器之藥物遞送裝置
US20210346596A1 (en) 2018-10-15 2021-11-11 Amgen Inc. Platform assembly process for drug delivery device
CN117138169A (zh) 2018-10-15 2023-12-01 安进公司 药物递送装置
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
MA54057A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
WO2020091956A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
US20220160972A1 (en) 2019-04-24 2022-05-26 Amgen Inc. Syringe sterilization verification assemblies and methods
WO2021041067A2 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
KR20240011135A (ko) 2021-05-21 2024-01-25 암젠 인크 약물 용기를 위한 충전 레시피를 최적화하는 방법
WO2023209074A1 (en) 2022-04-28 2023-11-02 Institut National de la Santé et de la Recherche Médicale Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
WO2024094457A1 (en) 2022-11-02 2024-05-10 F. Hoffmann-La Roche Ag Method for producing glycoprotein compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4954437A (en) * 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
WO1991005867A1 (en) * 1989-10-13 1991-05-02 Amgen Inc. Erythropoietin isoforms

Also Published As

Publication number Publication date
NO2007008I2 (no) 2011-02-21
CN1105030A (zh) 1995-07-12
DE69404401T2 (de) 1998-02-19
HK1001589A1 (en) 1998-06-26
EP0640619B2 (en) 2005-03-23
WO1995005465A1 (en) 1995-02-23
CN1057534C (zh) 2000-10-18
NO323104B1 (no) 2007-01-02
CA2147124C (en) 2002-11-05
DE10199059I1 (de) 2002-02-07
KR960701994A (ko) 1996-03-28
ATE155796T1 (de) 1997-08-15
JPH08506023A (ja) 1996-07-02
AU677097B2 (en) 1997-04-10
RU95115239A (ru) 1997-03-27
DK0640619T3 (da) 1998-02-02
DE69404401D1 (de) 1997-09-04
LV10972B (en) 1996-10-20
UA49793C2 (uk) 2002-10-15
JP2004331671A (ja) 2004-11-25
ES2105442T3 (es) 1997-10-16
JP2938572B2 (ja) 1999-08-23
IL136188A0 (en) 2001-07-24
FI117136B (fi) 2006-06-30
HU220334B (hu) 2001-12-28
GR3024815T3 (en) 1998-01-30
ZA946122B (en) 1995-03-20
LU90850I2 (fr) 2002-01-07
JPH11155584A (ja) 1999-06-15
IL110669A (en) 2008-11-26
FI951792A0 (fi) 1995-04-13
NO2007008I1 (no) 2007-07-23
NO951445L (no) 1995-06-16
SK50295A3 (en) 1995-08-09
NL300075I1 (nl) 2002-03-01
DE10199059I2 (de) 2007-11-08
DE69404401T3 (de) 2005-11-24
EP0640619B1 (en) 1997-07-23
HU9501435D0 (en) 1995-06-28
HUT72849A (en) 1996-05-28
CZ291342B6 (cs) 2003-02-12
AU7632794A (en) 1995-03-14
CZ291343B6 (cs) 2003-02-12
EP0640619A1 (en) 1995-03-01
SI0640619T1 (en) 1998-02-28
JP3664590B2 (ja) 2005-06-29
CZ291229B6 (cs) 2003-01-15
IL192290A0 (en) 2008-12-29
KR100328769B1 (ko) 2002-08-08
FI951792A (fi) 1995-05-18
NZ273134A (en) 1997-11-24
LV10972A (lv) 1995-12-20
CA2147124A1 (en) 1995-02-23
NL300075I2 (nl) 2002-04-02
JP3664723B2 (ja) 2005-06-29
NO951445D0 (no) 1995-04-12
RU2159814C2 (ru) 2000-11-27
SK282003B6 (sk) 2001-10-08
CZ91795A3 (en) 1996-03-13
IL110669A0 (en) 1994-11-11
SI0640619T2 (en) 2005-06-30
IL136189A0 (en) 2001-07-24
ES2105442T5 (es) 2005-07-16

Similar Documents

Publication Publication Date Title
DK0640619T4 (da) Erythropoietinanloger med yderligere glycosyleringssteder
DE69414543T2 (de) Verwendung von Zusammensetzungen zur Schaumregulierung
DE3885731D1 (de) Knochenschraube.
KR910006808A (ko) 피드백 제어 시스템
DK494589A (da) Substituerede 1,3,5-triazintrioner og deres anvendelse samt mellemprodukter til deres fremstilling
BR8906934A (pt) Transformador em matriz
DE59401268D1 (de) Eliminieren von abtaststörungen
ATA288188A (de) Fass
DK355289D0 (da) 2,2-dihalogencyclopropyl-hydroxy-ethyltriazoler, fremgangsmaader og mellemprodukter til deres fremstilling samt deres anvendelse
DE9310153U1 (de) Scheren-Verschraubung
KR910009665U (ko) 시간조절이 가능한 생활시간표
KR910010219U (ko) 팩시밀리의 콘트롤판넬 개폐장치
ITVR970024U4 (it) Manopola di comando
IT1179268B (it) Tastiera a membrana perfezionata e interruttore perfezionato per la realizzazione di detta tastiera
IT8404785V0 (it) Tastiera a membrana perfezionata e interruttore perfezionato per la realizzazione di detta tastiera
DE9305129U1 (de) Steuerungstastatur unter Verwendung von Piezo-Elementen
DK126890D0 (da) Knoglecement